retatrutide expanded access program eli lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly's Retatrutide Delivers Bariatric-Style

Active Ingredient: Lecithin, Bromeliad & Riboflavin (Vitamin B2) Highlights: Unique Formulation: Unlike most other fat dissolvers on the market, Lemon Bottle is formulated with a unique blend of ingredients for enhanced fat cell response including Riboflavin, Lecithin and Bromeliad

The mechanistic story is plausible and, in places, elegant

For digital information (the type stored by computers), those data typically are numbers stored in a binary code, portrayed as strings of zeros and ones

Professional liability considerations may differ from those associated with FDA-approved medications, and providers should maintain comprehensive documentation of treatment rationale and patient consent

Retatrutide Phase 2 reported 4%, matching placebo

FG reports consultancies or paid advisory board memberships for Eli Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi